AK
Anshu Kuriakose
Syngene International (India), Biofusion Therapeutics, Vellore Institute of Technology University, Biocon (India)
0000-0001-5921-9734
Employment
-
Syngene International (India) Principal Scientist2022 - Present
-
Biofusion Therapeutics Associate Principal Scientist2021 - 2022
-
Biocon (India) Associate Scientific Manager I2012 - 2021
Education
-
Vellore Institute of Technology University M.Sc Biotechnology2009 - 2011
Projects & Funding
Projects & funding information is unavailable.
Publications (16)
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save